| 1 |
A Study of Efficacy and Safety of Ianalumab in Previously Treated Patients With Warm Autoimmune Hemolytic Anemia |
Warm Autoimmune Hemolytic Anemia (wAIHA) |
Biological: Ianalumab|Drug: Placebo |
Novartis Pharmaceuticals|Novartis |
Phase 3 |
NCT05648968 |
2022-12-30 |
| 2 |
A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants With Alpha (α)-Thalassemia |
Anemia |
Biological: Luspatercept|Drug: Placebo|Other: Best Supportive Care |
Bristol-Myers Squibb |
Phase 2 |
NCT05664737 |
2022-12-09 |
| 3 |
To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs |
Hepatitis A|Hep A |
Biological: Boryung Hepatitis A Vaccine Pre-Filled Syringe Inj. 0.5 mL|Biological: HAVRIX 720 Junior 0.5 mL |
Boryung Biopharma Co., Ltd. |
Phase 3 |
NCT05613127 |
2022-12-01 |
| 4 |
Efficacy of VTP-300 in Chronic Hepatitis B Infection |
Chronic Hepatitis B |
Biological: ChAdOx1-HBV|Biological: MVA-HBV|Biological: Nivolumab |
Vaccitech (UK) Limited |
Phase 2 |
NCT05343481 |
2022-09-21 |
| 5 |
A Research Study to Compare Somapacitan Once a Week With Norditropin® Once a Day in Children Who Need Help to Grow |
SGA, Turner Syndrome, Noonan Syndrome, ISS |
Drug: Somapacitan|Drug: Norditropin® |
Novo Nordisk A/S |
Phase 3 |
NCT05330325 |
2022-08-10 |
| 6 |
Tezepelumab Efficacy and Safety in Reducing Oral Corticosteroid Use in Adults With Oral Corticosteroid Dependent Asthma |
Asthma |
Biological: Tezepelumab|Other: Placebo |
AstraZeneca|Amgen |
Phase 3 |
NCT05398263 |
2022-08-09 |
| 7 |
A Study to Evaluate Immunogenicity and Safety of MVC-COV1901 Compared With AZD1222 in Adults Aged 18 Years and Above |
COVID-19 Vaccine |
Biological: MVC-COV1901|Biological: AZD1222 |
Medigen Vaccine Biologics Corp. |
Phase 3 |
NCT05198596 |
2022-07-30 |
| 8 |
A Study of Combination Therapies With Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer (MK-3475-06A) |
Esophageal Squamous Cell Carcinoma (ESCC) |
Biological: Pembrolizumab|Biological: Coformulation favezelimab/pembrolizumab|Drug: MK-4830|Drug: Lenvatinib|Drug: Irinotecan|Drug: Paclitaxel |
Merck Sharp & Dohme LLC |
Phase 1|Phase 2 |
NCT05342636 |
2022-07-27 |
| 9 |
Safety and Immunogenicity of V116 in Adults Living With Human Immunodeficiency Virus (HIV) (V116-007, STRIDE-7) |
Pneumococcal Disease |
Biological: V116|Biological: Placebo|Biological: PCV15|Biological: PPSV23 |
Merck Sharp & Dohme LLC |
Phase 3 |
NCT05393037 |
2022-07-13 |
| 10 |
ERC1671 to Treat Malignant Gliomas When Given in Combination With GM-CSF, Cyclophosphamide, Bevacizumab and Pembrolizumab |
Glioma, Malignant |
Drug: ERC1671|Drug: GM-CSF|Drug: Cyclophosphamide|Drug: Pembrolizumab |
Epitopoietic Research Corporation |
Phase 2 |
NCT05366062 |
2022-07-01 |
이 누리집은 대한민국 공식 전자정부 누리집입니다.